These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 33958533)

  • 61. Follow-up to Age 4 Years of Treatment of Type 1 Retinopathy of Prematurity Intravitreal Bevacizumab Injection versus Laser: Fluorescein Angiographic Findings.
    Lepore D; Quinn GE; Molle F; Orazi L; Baldascino A; Ji MH; Sammartino M; Sbaraglia F; Ricci D; Mercuri E
    Ophthalmology; 2018 Feb; 125(2):218-226. PubMed ID: 28867130
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Serum concentrations of bevacizumab (avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity.
    Sato T; Wada K; Arahori H; Kuno N; Imoto K; Iwahashi-Shima C; Kusaka S
    Am J Ophthalmol; 2012 Feb; 153(2):327-333.e1. PubMed ID: 21930258
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Comparison of clinical outcomes of intravitreal ranibizumab and aflibercept treatment for retinopathy of prematurity.
    Sukgen EA; Koçluk Y
    Graefes Arch Clin Exp Ophthalmol; 2019 Jan; 257(1):49-55. PubMed ID: 30397793
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Low-dose ranibizumab as primary treatment of posterior type I retinopathy of prematurity.
    Ells AL; Wesolosky JD; Ingram AD; Mitchell PC; Platt AS
    Can J Ophthalmol; 2017 Oct; 52(5):468-474. PubMed ID: 28985806
    [TBL] [Abstract][Full Text] [Related]  

  • 65. The severity and associated comorbidities of retinopathy of prematurity among micro-premature infants with birth weights less than 750 grams.
    Beck K; Young R; Read S; Harper H; Desireddi J; Harper CA
    J Neonatal Perinatal Med; 2019; 12(1):41-45. PubMed ID: 30400108
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Prospective clinical study of two different treatment regimens of combined laser photocoagulation and intravitreal bevacizumab for retinopathy of prematurity: the Indian Twin Cities ROP Study (ITCROPS) database report number 9.
    Laveti V; Balakrishnan D; Rani PK; Mohamed A; Jalali S
    Int Ophthalmol; 2020 Dec; 40(12):3539-3545. PubMed ID: 32776299
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Repeated intravitreal ranibizumab for reactivated retinopathy of prematurity after intravitreal ranibizumab monotherapy: vascular development analysis.
    Xia F; Lyu J; Peng J; Zhao P
    Graefes Arch Clin Exp Ophthalmol; 2022 Sep; 260(9):2837-2846. PubMed ID: 35438363
    [TBL] [Abstract][Full Text] [Related]  

  • 68. New trends in intravitreal anti-VEGF therapy for ROP.
    Beccasio A; Mignini C; Caricato A; Iaccheri B; Di Cara G; Verrotti A; Cagini C
    Eur J Ophthalmol; 2022 May; 32(3):1340-1351. PubMed ID: 35040348
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Refractive Error in Patients with Retinopathy of Prematurity after Laser Photocoagulation or Bevacizumab Monotherapy.
    Kuo HK; Sun IT; Chung MY; Chen YH
    Ophthalmologica; 2015; 234(4):211-7. PubMed ID: 26393895
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [Retinopathy of prematurity - therapy. Part 2].
    Prepiaková Z; Tomčíková D; Kostolná B; Gerinec A
    Cesk Slov Oftalmol; 2014 Apr; 70(2):50-4. PubMed ID: 25030312
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Increase in treatment of retinopathy of prematurity in the Netherlands from 2010 to 2017.
    Trzcionkowska K; Vehmeijer WBHJ; Kerkhoff FT; Bauer NJC; Bennebroek CAM; Dijk PH; Dijkman KP; van den Dungen FAM; Eggink CA; Feenstra RPG; Groenendaal F; van Heijst AF; van der Hoeven MAHBM; Kornelisse RF; Kraal-Biezen E; Lopriore E; Onland W; Renardel de Lavalette VW; van Rijn LJ; Schuerman FABA; Simonsz HJ; Voskuil-Kerkhof ESM; Witlox RSGM; Termote JUM; Schalij-Delfos NE
    Acta Ophthalmol; 2021 Feb; 99(1):97-103. PubMed ID: 32701185
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Assessment of vascular leakage and its development with FFA among patients treated with intravitreal anti-VEGF due to aggressive posterior ROP.
    Ekinci DY; Vural AD; Bayramoglu SE; Onur IU; Hergunsel GO
    Int Ophthalmol; 2019 Dec; 39(12):2697-2705. PubMed ID: 30830544
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Comparison of the effectiveness of conbercept and ranibizumab treatment for retinopathy of prematurity.
    Cheng Y; Zhu X; Linghu D; Liang J
    Acta Ophthalmol; 2020 Dec; 98(8):e1004-e1008. PubMed ID: 32385940
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Recurrence of Retinopathy of Prematurity After Intravitreal Ranibizumab Monotherapy: Timing and Risk Factors.
    Lyu J; Zhang Q; Chen CL; Xu Y; Ji XD; Li JK; Huang QJ; Zhao PQ
    Invest Ophthalmol Vis Sci; 2017 Mar; 58(3):1719-1725. PubMed ID: 28324112
    [TBL] [Abstract][Full Text] [Related]  

  • 75. CLINICAL FEATURES AND OUTCOMES OF INFANTS WITH RETINOPATHY OF PREMATURITY WHO FAIL ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY.
    Xu LT; Levine DA; Hutchinson AK; Rao P; Hubbard GB
    Retina; 2021 Nov; 41(11):2269-2277. PubMed ID: 34190725
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Intravitreal bevacizumab monotherapy for type-1 prethreshold, threshold, and aggressive posterior retinopathy of prematurity - 27 month follow-up results from Turkey.
    Yetik H; Gunay M; Sirop S; Salihoglu Z
    Graefes Arch Clin Exp Ophthalmol; 2015 Oct; 253(10):1677-83. PubMed ID: 25501298
    [TBL] [Abstract][Full Text] [Related]  

  • 77. The role of anti-vascular endothelial growth factor in treatment of retinopathy of prematurity-a current review.
    Chow SC; Lam PY; Lam WC; Fung NSK
    Eye (Lond); 2022 Aug; 36(8):1532-1545. PubMed ID: 35017699
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Low- and Very Low-Dose Bevacizumab for Retinopathy of Prematurity: Reactivations, Additional Treatments, and 12-Month Outcomes.
    Freedman SF; Hercinovic A; Wallace DK; Kraker RT; Li Z; Bhatt AR; Boente CS; Crouch ER; Hubbard GB; Rogers DL; VanderVeen D; Yang MB; Cheung NL; Cotter SA; Holmes JM;
    Ophthalmology; 2022 Oct; 129(10):1120-1128. PubMed ID: 35660415
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Ocular complications following treatment in the Postnatal Growth and Retinopathy of Prematurity (G-ROP) Study.
    Morrison D; Shaffer J; Ying GS; Binenbaum G;
    J AAPOS; 2018 Apr; 22(2):128-133. PubMed ID: 29548840
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Favorable outcomes in the treatment of aggressive posterior retinopathy of prematurity.
    Sahinoglu-Keskek N; Akkoyun I; Torer B
    Eur J Ophthalmol; 2021 Jan; 31(1):179-183. PubMed ID: 31718282
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.